Revolution Medicines joined the Russell 1000 Growth Benchmark on June 29, 2026. This inclusion increases the company's visibility among institutional investors tracking the index.
Needham & Company LLC raised its price target for RVMD to $235.00 from $183.00 on the same day. The firm maintained its buy rating for the stock. This new price objective suggests a potential upside of over 29% from current levels.